{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:22:33Z","timestamp":1769606553174,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T00:00:00Z","timestamp":1376265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ygyno.2013.08.009","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T18:02:15Z","timestamp":1376416935000},"page":"362-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer"],"prefix":"10.1016","volume":"131","author":[{"given":"Thomas","family":"Rutherford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James","family":"Orr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Edward","family":"Grendys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Puls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Tillmanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian C.","family":"Schink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey L.","family":"Brower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunqiao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.08.009_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/GRF.0b013e31824b9bc5","article-title":"A rational approach to the management of recurrent or persistent ovarian carcinoma","volume":"55","author":"Thigpen","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0015","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","article-title":"Evolution of platinum resistance in high-grade serous ovarian cancer","volume":"12","author":"Cooke","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0030","author":"Kris"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/gyno.2002.6797","article-title":"Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients","volume":"87","author":"Holloway","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1179\/joc.2010.22.4.270","article-title":"Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer","volume":"22","author":"Pant","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2009.09.018","article-title":"Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma","volume":"116","author":"Matsuo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1525-1438.2006.00301.x","article-title":"Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay","volume":"16","author":"Gallion","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"68","key":"10.1016\/j.ygyno.2013.08.009_bb0055","first-page":"e1","article-title":"Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer","volume":"203","author":"Herzog","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2009.08.027","article-title":"Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer","volume":"116","author":"Holloway","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0065","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1002\/ijc.24654","article-title":"Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer","volume":"125","author":"Matsuo","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/GCO.0b013e32832210ff","article-title":"Chemosensitivity and chemoresistance testing in ovarian cancer","volume":"21","author":"Cree","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.6004\/jnccn.2011.0009","article-title":"Point: chemosensitivity assays have a role in the management of recurrent ovarian cancer","volume":"9","author":"Schink","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0080","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","article-title":"Reporting recommendations for tumor marker prognostic studies","volume":"23","author":"McShane","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1373\/49.1.7","article-title":"The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration","volume":"49","author":"Bossuyt","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0090","series-title":"Methods in molecular biology, apoptosis and cancer","first-page":"57","article-title":"The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy","volume":"vol. 414","author":"Brower","year":"2008"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0095","first-page":"7","article-title":"Robotic liquid handlers and semiautomated cell quantification systems increase consistency and reproducibility in high-throughput, cell-based assay","volume":"15","author":"Heinzman","year":"2010","journal-title":"JALA"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0100","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0105","series-title":"Ovarian cancer: including fallopian tube cancer and primary peritoneal cancer. Version 1.2013","article-title":"NCCN clinical practice guidelines in oncology","author":"Comprehensive Cancer Network","year":"2013"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0110","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/CAD.0b013e3281de727e","article-title":"A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer","volume":"18","author":"Cree","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0115","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1158\/1078-0432.CCR-04-0496","article-title":"Evaluating the efficiency of targeted designs for randomized clinical trials","volume":"10","author":"Simon","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0120","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2005.01.112","article-title":"Clinical trial designs for predictive marker validation in cancer treatment trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jnci\/djp477","article-title":"Randomized clinical trials with biomarkers: design issues","volume":"102","author":"Freidlin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0130","author":"Deverka"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0145","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent ovarian cancer: how important is it to treat to disease progression?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0150","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase III trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0155","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.ygyno.2013.08.009_bb0160","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0165","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.08.009_bb0170","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1067\/S0002-9378(03)00629-X","article-title":"Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy","volume":"189","author":"Loizzi","year":"2003","journal-title":"Am J Obstet Gynecol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813010949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813010949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T20:52:53Z","timestamp":1539463973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813010949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0090825813010949"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.08.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}